-
Uncategorized1 month ago
Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst Pharma
Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst Pharma
-
Uncategorized1 month agoSTAT+: Color me skeptical: Drinking gold is not an ALS cure
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. It’s been a...
-
Uncategorized1 month agoSTAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
The Italian company Angelini Pharma said Thursday it would buy the rare-disease focused Catalyst Pharmaceuticals for roughly $4.1 billion in cash. The deal values Florida-based Catalyst...
-
Uncategorized1 month ago
Fibrosis, IPF and the search for better therapies
In this episode of Denatured, you’ll be hearing from Georg Vo Beiske, CEO of Tribune Therapeutics and Jonas Hallén, co-founder and Chief Medical Officer of Calluna...
-
Uncategorized1 month ago
Scientists accidentally discover DNA that breaks the rules of life
A routine experiment with a new single-cell DNA sequencing method turned into a surprising scientific twist when researchers stumbled upon a bizarre genetic code in a...
-
Uncategorized1 month ago
Winning the room: how to ace panel interviews
Panel interviews can play a major role in getting jobs. Two career coaches discuss what to do before and during the interview, including identifying how to...
-
Uncategorized1 month ago
Increased capital boosts biotech R&D job postings, employment
Biotech R&D job postings live on BioSpace rose for the fourth straight month in April, and a CBRE report shared similar findings for employment. The head...
-
Uncategorized1 month ago
3 top FDA, CDC roles filled by 15 different people in less than 18 months
3 top FDA, CDC roles filled by 15 different people in less than 18 months
-
Uncategorized1 month ago
Bayer to Acquire Perfuse for up to $2.45B, Seeing Ophthalmology Opportunity
Bayer has agreed to acquire Perfuse Therapeutics for up to $2.45 billion, the companies said, in a deal designed to broaden the buyer’s ophthalmology pipeline with...
-
Uncategorized1 month ago
Newcomer anti-IL-33 makes strides in COPD
Nature Biotechnology, Published online: 07 May 2026; doi:10.1038/s41587-026-03136-x AstraZeneca’s IL-33 antibody tozorakimab targets two distinct signaling pathways engaged in COPD: inflammation and epithelial dysfunction.
